FDA Approves Zytiga Plus Prednisone for Earlier Form of Metastatic Prostate Cancer

FDA Approves Zytiga Plus Prednisone for Earlier Form of Metastatic Prostate Cancer
Zytiga (abiraterone acetate) is now approved in the U.S. to treat metastatic high-risk castration-sensitive prostate cancer (CSPC) in combination with prednisone, Janssen Pharmaceutical Companies announced. The U.S. Food and Drug Administration (FDA) granted its approval following results of the Phase 3 LATITUDE trial (NCT01715285), which showed that the combo therapy reduced the risk of death

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *